A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections

Noboru Yamanaka, Satoshi Iwata, Kyoichi Totsuka, Yoshio Aizawa, Seiji Hori, Naoichi Iwai, Kimiko Ubukata, Keisuke Sunakawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We conducted a phase II open clinical study in pediatric patients with acute otitis media and acute rhinosinusitis to assess efficacy, safety, and drug compliance with TBPM-PI 4 mg/kg bid and 6 mg/kg bid administration. 1. Clinical effect: Efficacy at the end of administration or at discontinuation was 100% (11/11) in the 4 mg/kg bid group and 100% (10/ 10) in the 6 mg/kg bid group, showing good clinical effect in all subjects. 2. Bacteriological effect: Isolated causal microorganisms were 5 strains of Streptococcus pneumoniae, 4 strains of Haemophilus influenzae, and 2 strains of Moraxella catarrhalis. Eradication at the end of administration or at discontinuation was 90.9% (10/11) in all subjects. All strains excluding 1 strain of H. influenzae in the 6 mg/kg bid were eradicated. 3. Safety: The incidence of adverse drug reactions associated with subjective symptoms and objective findings was 28.0% (7/25) in all subjects, consisting of 33.3% (4/12) in the 4 mg/kg bid and 23.1% (3/13) in the 6 mg/kg. Common adverse drug reactions were diarrhea and loose stool. No adverse drug reactions were associated with clinical laboratory tests in any treatment group. 4. Drug compliance: Compliance was 96.0% (24/25) in both treatment groups, i.e., 100% (12/12) in the 4 mg/kg bid group and 92.3% (12/13) in the 6 mg/kg bid group. Compliance in the age group of ≥ 3 years old and < 6 years old was 92.9% (13/14) and 100% (11/11) in the age group of < 3 years old. Sufficient clinical and bacteriological effects were noted in the 4 mg/ kg bid group of the dose converted by that from the adult study, and no specific clinical problem occurred in safety. The recommended clinical dose for pediatric patients with acute otitis media and acute rhinosinusitis was therefore 4 mg/kg bid.

Original languageEnglish
Pages (from-to)125-136
Number of pages12
JournalJapanese Journal of Chemotherapy
Volume57
Issue numberSUPPL. 1
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Haemophilus influenzae
Otitis Media
Clinical Trials
Pediatrics
Safety
Compliance
Age Groups
Infection
Moraxella (Branhamella) catarrhalis
Streptococcus pneumoniae
Pharmaceutical Preparations
Diarrhea
Therapeutics
Incidence
Clinical Studies
tebipenem

Keywords

  • Acute otitis media
  • Acute rhinosinusitis
  • Compliance
  • Oral carbapenem
  • PK-PD
  • Tebipenem pivoxil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Yamanaka, N., Iwata, S., Totsuka, K., Aizawa, Y., Hori, S., Iwai, N., ... Sunakawa, K. (2009). A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections. Japanese Journal of Chemotherapy, 57(SUPPL. 1), 125-136.

A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections. / Yamanaka, Noboru; Iwata, Satoshi; Totsuka, Kyoichi; Aizawa, Yoshio; Hori, Seiji; Iwai, Naoichi; Ubukata, Kimiko; Sunakawa, Keisuke.

In: Japanese Journal of Chemotherapy, Vol. 57, No. SUPPL. 1, 03.2009, p. 125-136.

Research output: Contribution to journalArticle

Yamanaka, N, Iwata, S, Totsuka, K, Aizawa, Y, Hori, S, Iwai, N, Ubukata, K & Sunakawa, K 2009, 'A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections', Japanese Journal of Chemotherapy, vol. 57, no. SUPPL. 1, pp. 125-136.
Yamanaka, Noboru ; Iwata, Satoshi ; Totsuka, Kyoichi ; Aizawa, Yoshio ; Hori, Seiji ; Iwai, Naoichi ; Ubukata, Kimiko ; Sunakawa, Keisuke. / A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections. In: Japanese Journal of Chemotherapy. 2009 ; Vol. 57, No. SUPPL. 1. pp. 125-136.
@article{d70d695958ac40ef8d701fad49488ebc,
title = "A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections",
abstract = "We conducted a phase II open clinical study in pediatric patients with acute otitis media and acute rhinosinusitis to assess efficacy, safety, and drug compliance with TBPM-PI 4 mg/kg bid and 6 mg/kg bid administration. 1. Clinical effect: Efficacy at the end of administration or at discontinuation was 100{\%} (11/11) in the 4 mg/kg bid group and 100{\%} (10/ 10) in the 6 mg/kg bid group, showing good clinical effect in all subjects. 2. Bacteriological effect: Isolated causal microorganisms were 5 strains of Streptococcus pneumoniae, 4 strains of Haemophilus influenzae, and 2 strains of Moraxella catarrhalis. Eradication at the end of administration or at discontinuation was 90.9{\%} (10/11) in all subjects. All strains excluding 1 strain of H. influenzae in the 6 mg/kg bid were eradicated. 3. Safety: The incidence of adverse drug reactions associated with subjective symptoms and objective findings was 28.0{\%} (7/25) in all subjects, consisting of 33.3{\%} (4/12) in the 4 mg/kg bid and 23.1{\%} (3/13) in the 6 mg/kg. Common adverse drug reactions were diarrhea and loose stool. No adverse drug reactions were associated with clinical laboratory tests in any treatment group. 4. Drug compliance: Compliance was 96.0{\%} (24/25) in both treatment groups, i.e., 100{\%} (12/12) in the 4 mg/kg bid group and 92.3{\%} (12/13) in the 6 mg/kg bid group. Compliance in the age group of ≥ 3 years old and < 6 years old was 92.9{\%} (13/14) and 100{\%} (11/11) in the age group of < 3 years old. Sufficient clinical and bacteriological effects were noted in the 4 mg/ kg bid group of the dose converted by that from the adult study, and no specific clinical problem occurred in safety. The recommended clinical dose for pediatric patients with acute otitis media and acute rhinosinusitis was therefore 4 mg/kg bid.",
keywords = "Acute otitis media, Acute rhinosinusitis, Compliance, Oral carbapenem, PK-PD, Tebipenem pivoxil",
author = "Noboru Yamanaka and Satoshi Iwata and Kyoichi Totsuka and Yoshio Aizawa and Seiji Hori and Naoichi Iwai and Kimiko Ubukata and Keisuke Sunakawa",
year = "2009",
month = "3",
language = "English",
volume = "57",
pages = "125--136",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A open clinical trial study of tebipenem pivoxil fine granule for treatment of pediatric patients with otorlaryngological infections

AU - Yamanaka, Noboru

AU - Iwata, Satoshi

AU - Totsuka, Kyoichi

AU - Aizawa, Yoshio

AU - Hori, Seiji

AU - Iwai, Naoichi

AU - Ubukata, Kimiko

AU - Sunakawa, Keisuke

PY - 2009/3

Y1 - 2009/3

N2 - We conducted a phase II open clinical study in pediatric patients with acute otitis media and acute rhinosinusitis to assess efficacy, safety, and drug compliance with TBPM-PI 4 mg/kg bid and 6 mg/kg bid administration. 1. Clinical effect: Efficacy at the end of administration or at discontinuation was 100% (11/11) in the 4 mg/kg bid group and 100% (10/ 10) in the 6 mg/kg bid group, showing good clinical effect in all subjects. 2. Bacteriological effect: Isolated causal microorganisms were 5 strains of Streptococcus pneumoniae, 4 strains of Haemophilus influenzae, and 2 strains of Moraxella catarrhalis. Eradication at the end of administration or at discontinuation was 90.9% (10/11) in all subjects. All strains excluding 1 strain of H. influenzae in the 6 mg/kg bid were eradicated. 3. Safety: The incidence of adverse drug reactions associated with subjective symptoms and objective findings was 28.0% (7/25) in all subjects, consisting of 33.3% (4/12) in the 4 mg/kg bid and 23.1% (3/13) in the 6 mg/kg. Common adverse drug reactions were diarrhea and loose stool. No adverse drug reactions were associated with clinical laboratory tests in any treatment group. 4. Drug compliance: Compliance was 96.0% (24/25) in both treatment groups, i.e., 100% (12/12) in the 4 mg/kg bid group and 92.3% (12/13) in the 6 mg/kg bid group. Compliance in the age group of ≥ 3 years old and < 6 years old was 92.9% (13/14) and 100% (11/11) in the age group of < 3 years old. Sufficient clinical and bacteriological effects were noted in the 4 mg/ kg bid group of the dose converted by that from the adult study, and no specific clinical problem occurred in safety. The recommended clinical dose for pediatric patients with acute otitis media and acute rhinosinusitis was therefore 4 mg/kg bid.

AB - We conducted a phase II open clinical study in pediatric patients with acute otitis media and acute rhinosinusitis to assess efficacy, safety, and drug compliance with TBPM-PI 4 mg/kg bid and 6 mg/kg bid administration. 1. Clinical effect: Efficacy at the end of administration or at discontinuation was 100% (11/11) in the 4 mg/kg bid group and 100% (10/ 10) in the 6 mg/kg bid group, showing good clinical effect in all subjects. 2. Bacteriological effect: Isolated causal microorganisms were 5 strains of Streptococcus pneumoniae, 4 strains of Haemophilus influenzae, and 2 strains of Moraxella catarrhalis. Eradication at the end of administration or at discontinuation was 90.9% (10/11) in all subjects. All strains excluding 1 strain of H. influenzae in the 6 mg/kg bid were eradicated. 3. Safety: The incidence of adverse drug reactions associated with subjective symptoms and objective findings was 28.0% (7/25) in all subjects, consisting of 33.3% (4/12) in the 4 mg/kg bid and 23.1% (3/13) in the 6 mg/kg. Common adverse drug reactions were diarrhea and loose stool. No adverse drug reactions were associated with clinical laboratory tests in any treatment group. 4. Drug compliance: Compliance was 96.0% (24/25) in both treatment groups, i.e., 100% (12/12) in the 4 mg/kg bid group and 92.3% (12/13) in the 6 mg/kg bid group. Compliance in the age group of ≥ 3 years old and < 6 years old was 92.9% (13/14) and 100% (11/11) in the age group of < 3 years old. Sufficient clinical and bacteriological effects were noted in the 4 mg/ kg bid group of the dose converted by that from the adult study, and no specific clinical problem occurred in safety. The recommended clinical dose for pediatric patients with acute otitis media and acute rhinosinusitis was therefore 4 mg/kg bid.

KW - Acute otitis media

KW - Acute rhinosinusitis

KW - Compliance

KW - Oral carbapenem

KW - PK-PD

KW - Tebipenem pivoxil

UR - http://www.scopus.com/inward/record.url?scp=65249180832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249180832&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65249180832

VL - 57

SP - 125

EP - 136

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -